APVO - Aptevo Therapeutics Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

APVO

APTEVO THERAPEUTICS INC.

NASDAQ

$2.37

▼ DOWN 2.27% (-0.06)

KEY STATISTICS

Market Cap$5.17 M

52w High$48.78

52w Low$2.30

Dividend Yield—

Frequency—

P/E—

Volume20.99K

Shares Out.1.25M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Jeffrey G. Lamothe

COMPENSATION 2026

Salary$630,269

Stock Awards$79

Incentive Plan Pay$236,555

All Other Comp.$10,500

Total$1,277,403

ABOUT

SECTOR

Healthcare

WENT PUBLIC

July 20, 2016

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.—

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2025-12-30	Reverse	1:18
2025-05-27	Reverse	1:20
2024-12-04	Reverse	1:37
2024-03-06	Reverse	1:44
2020-03-27	Reverse	1:14

PRICE

$2.37 ▼ DOWN 2.27% (−$0.06)

OVERLAYS

About Aptevo Therapeutics Inc.

https://www.aptevotherapeutics.com ↗

Aptevo Therapeutics Inc. is a Seattle-based clinical-stage biotech developing immunotherapies for cancer, with lead candidate APVO436 in Phase 1b trials and several preclinical bispecific antibodies targeting various tumor antigens.

INDUSTRY

Biotechnology

A PRODUCT APTEVO THERAPEUTICS INC. IS KNOWN FOR

Mipletamig (APVO436)

Mipletamig, Aptevo's leading proprietary drug for AML, is an antibody-like therapeutic in Phase 1b/2 trials that engages leukemic cells and T-cells to induce cancer cell destruction.